Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOD-4023 OLE in pediatric GHD
NCT02500316Phase 2Completed
- Sponsor
- OPKO Health
- Start
- Feb 2014
- Primary completion
- Nov 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 2 trial of somatrogon in growth hormone deficiency (GHD), sponsored by OPKO Health. Started Feb 2014; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02500316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500316.